Trial Profile
An exploratory, observational study to evaluate the efficacy and safety of daptomycin in treating neutropenic patients with fever due to known or suspected gram positive infections in adult hemato-oncology patients.
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 12 Nov 2019
Price :
$35
*
At a glance
- Drugs Daptomycin (Primary)
- Indications Febrile neutropenia; Gram-positive infections
- Focus Therapeutic Use
- Sponsors Novartis
- 15 Apr 2013 New trial record